Work

A phase III randomized trial of pembrolizumab in combination with sacituzumab govitecan vs standard of care in anti–PD-(L)1–resistant advanced urothelial cancer: ECOG-ACRIN EA8231.

Year: 2026

Type: article

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.tps4641

Authors: Monika Joshi, Se Eun Kim, Petros Grivas, Elizabeth Wulff, Alicia K. Morgans, Kriti Mittal, Joshua Warrick, Melissa A. Reimers, Noah M. Hahn, Naomi Balzer Haas, Lynne I. Wagner, Michael A. Carducci

Institutions: Penn State Cancer Institute, Penn State Milton S. Hershey Medical Center, Dana-Farber Cancer Institute, University of Washington, Fred Hutch Cancer Center, University of Kansas Medical Center, University of Massachusetts Chan Medical School, Yale University, Washington University in St. Louis, Johns Hopkins University, Abramson Cancer Center, University of Pennsylvania, University of North Carolina at Chapel Hill

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162684990

FWCI:

Cites:

Cited by:

Related to: